Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
27/03/2026 19:01
March 27 (Reuters) - SUN PHARMA: PARTNER PHILOGEN'S PHASE II FLASH STUDY IN SOFT TISSUE SARCOMA DID NOT MEET PRIMARY ENDPOINT PHILOGEN'S PHASE II GLIOSTAR TRIAL IN GLIOBLASTOMA DID NOT MEET PRIMARY ENDPOINT PHILOGEN REMAINS COMMITTED TO EXECUTION OF GLIOSUN CLINICAL TRIAL Source text: ID:nBSE70fvgH Further company coverage: PHIL.MI ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Philogen
See all newsBrief: Philogen H1 Net Loss €19.6 Mln
Brief: Philogen Resubmits To EMA Marketing Authorization Application For Nidlegy
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Brief: Philogen Reports FY EBITDA Of EUR 261.6 Million
Brief: Philogen H1 Net Loss EUR 14,894